In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products

• Main Authors: Ming-Jen Sheu, Chi-Chung Chen, Ying-Chen Lu, Bo-An Su, Chun-Cheng Zhang, Shu-Shen Wang, Yin-Ching Chuang, Hung-Jen Tang, Chih-Cheng Lai
• Format: Article
• Language: English
• Published: MDPI AG 2020-02-01
• Series: Antibiotics
• Subjects: cefoperazone/sulbactam; multidrug-resistant organism; antimicrobial activity
• Online Access: https://www.mdpi.com/2079-6382/9/2/77

This study aims to assess the in vitro activity of different samples of cefoperazone/sulbactam (CFP/SUL) against multidrug-resistant organisms (MDROs). Clinical isolates of extended-spectrum &#946;-lactamase (ESBL)-<i>Escherichia coli</i>, ESBL-<i>Klebsiella pneumoniae</i>, carbapenem-resistant <i>Acinetobacter baumannii</i> (CR-AB), and carbapenem-resistant <i>Pseudomonas aeruginosa</i> (CR-PA) were collected. The minimum inhibitory concentration (MIC) and time-killing methods were used to assess and compare the in vitro activities of different samples of cefoperazone/sulbactam (CFP/SUL) against these MDROs. For ESBL-<i>E. coli</i>, ESBL-<i>K. pneumoniae</i>, and CR-PA, product C had smaller variations than product A and B (<i>p</i> &lt; 0.05). For CR-AB, product B had the largest variation compared to the other two products (<i>p</i> &lt; 0.05). In the time-killing studies, significant differences among the products when used at 16/16 &#181;g/mL were noted for ESBL-<i>E. coli</i>, ESBL-<i>K. pneumoniae</i>, and CR-AB isolates. In conclusion, this study demonstrated the significantly different activity of different products of CFP/SUL against MDROs.